Home › Funds › Merck & Co., Inc. › VRDN

Merck & Co., Inc. position in VRDN

VIRIDIAN THERAPEUTICS INC · Health Care

Merck & Co., Inc. reported holding 93,414 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.9M, representing 0.23% of its reported portfolio and ranking #10 among its reported holdings. Merck & Co., Inc. has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)93.41K sh
Reported value held$1.92M
Portfolio Weight0.23%
First reportedQ4 2024
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Merck & Co., Inc.'s VRDN position evolved

Merck & Co., Inc. first disclosed a stake in VRDN in Q4 2024 at 93,414 shares (US$1.8M). The position peaked in Q4 2025 at 93,414 shares, worth US$2.9M. Across 8 filings, Merck & Co., Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 93,414 shares valued at US$1.9M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 93.41K $1.79M New
Q1 2025 93.41K $1.26M Hold
Q2 2025 93.41K $1.31M Hold
Q3 2025 93.41K $2.02M Hold
Q4 2025 93.41K $2.91M Hold
Q1 2026 93.41K $1.83M Hold
Q2 2026 93.41K $1.72M Hold
Q3 2026 93.41K $1.92M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRDN and 13F data

VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRDN

All VRDN fund holders →

FAQ

How long has Merck & Co., Inc. held VRDN?

Merck & Co., Inc. has disclosed VRDN holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Merck & Co., Inc.'s current position in VRDN?

As of Q3 2026, Merck & Co., Inc. holds 93.41K shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $1.92M, representing 0.23% of its reported portfolio and ranking #10.

Has Merck & Co., Inc. been buying or selling VRDN?

In the latest 13F filing (Q3 2026), Merck & Co., Inc. held unchanged its position in VRDN. The position peaked in Q4 2025 at 93.41K shares.

Which other funds hold VRDN?

Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.